Category: Bio & Healthcare

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Korea Exchange (KRX) issued an advance notice regarding planned market measures—including adjustments to base prices, trading multipliers, and strike prices for ALTEOGEN stock futures and options—effective August 5, 2026 (ex-rights date) following a bonus issue. 📊 [Key Disclosure Details & Major Figures Summary] 📝 Editor’s Comment…

Read More “[Disclosure] ALTEOGEN (196170) – Advance Notice of Market Measures on Stock Futures and Options (Bonus Issue) / 2026-07-23” »

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Samsung Biologics reported Q2 2026 consolidated revenue of KRW 1.32T and operating profit of KRW 586.4B, marking a year-over-year increase of 30.2% and 22.9%, respectively. 📊 [Key Disclosure Details & Financial Summary] 📝 Editor’s Comment (Key Follow-up Checkpoint) 📌 Verification of External Auditor’s Review and Final…

Read More “[Disclosure] Samsung Biologics (207940) – Consolidated Financial Results (Preliminary) / 2026-07-23” »

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary ALTEOGEN submitted a correction disclosure updating the expected listing date of new shares for its bonus issue from August 20, 2026, to August 26, 2026, following consultations with relevant authorities. 📊 [Key Disclosure Details & Major Figures Summary] 📝 Editor’s Comment (Key Follow-up Checkpoint) 📌 Verification…

Read More “[Disclosure] ALTEOGEN (196170) – (Correction) Decision on Bonus Issue / 2026-07-20” »

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Samsung Biologics has decided to acquire 33,016,411 shares of PolyPeptide Group AG, a Swiss peptide CDMO specialist, for approximately KRW 2.71T through a tender offer to strengthen its business competitiveness. 📊 [Key Disclosure Details & Financial Summary] 📝 Editor’s Comment (Key Follow-up Checkpoint) 📌 Satisfaction of…

Read More “[Disclosure] Samsung Biologics (207940) – Decision on Acquisition of Shares and Equity Securities of Other Corporation / 2026-07-20” »

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary ALTEOGEN set August 6, 2026, as the record date to determine eligible shareholders for the new share allotment of its bonus issue. 📊 [Key Disclosure Details & Major Figures Summary] 📝 Editor’s Comment (Key Follow-up Checkpoint) 📌 Verification of Shareholder Determination and Subsequent Bonus Issue Schedule…

Read More “[Disclosure] ALTEOGEN (196170) – Setting of Record Date or Closure Period of Shareholder Register / 2026-07-16” »

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Following market measures on the underlying stock, trading for ALTEOGEN stock futures and options will be suspended on July 16, 2026, at 15:31 and resumed on July 20, 2026, at 08:45. 📊 [Key Disclosure Details & Major Figures Summary] 📝 Editor’s Comment (Key Follow-up Checkpoint) 📌…

Read More “[Disclosure] ALTEOGEN (196170) – Trading Suspension and Resumption of Stock Futures and Options / 2026-07-16” »

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary ALTEOGEN decided to temporarily postpone applying for a preliminary review to move its listing from KOSDAQ to KOSPI, maintaining its KOSDAQ listing for now in consideration of recent capital market conditions and government policies. 📊 [Key Disclosure Details & Major Figures Summary] 📝 Editor’s Comment (Key…

Read More “[Disclosure] ALTEOGEN (196170) – Temporary Postponement of KOSPI Relisting / 2026-07-16” »

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Trading of ALTEOGEN common stock was suspended on July 16, 2026, from 15:31:00 until the close of the market following its bonus issue decision. 📊 [Key Disclosure Details & Major Figures Summary] 📝 Editor’s Comment (Key Follow-up Checkpoint) 📌 Verification of Subsequent Exchange Market Notices Regarding…

Read More “[Disclosure] ALTEOGEN (196170) – Suspension of Equity Trading (Bonus Issue) / 2026-07-16” »

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary ALTEOGEN announced a bonus issue allotting 0.3 new shares (30%) per existing common and other share. A total of 16,190,827 new shares will be issued, with a record date of August 6, 2026. 📊 [Key Disclosure Details & Major Figures Summary] 📝 Editor’s Comment (Key Follow-up…

Read More “[Disclosure] ALTEOGEN (196170) – Decision on Bonus Issue / 2026-07-16” »

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Celltrion has decided on the early termination and voluntary withdrawal of its Phase 3 clinical trial plan in Europe for CT-P51, a biosimilar to Keytruda (an immuno-oncology drug). This stems from an adjustment in clinical and regulatory approval strategy following changes in global regulatory trends, while…

Read More “[Disclosure] Celltrion (068270) – CT-P51 (Keytruda Biosimilar) Europe Phase 3 Early Termination & Voluntary Withdrawal of Trial Plan / 2026-07-14” »